利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

88 条记录 (耗时 0.033 秒)

    Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
    1.
    发明授权
    Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids 失效
    使用四氢皮质醇来防止由皮质类固醇引起的眼压升高

    公开(公告)号：US5358943A

    公开(公告)日：1994-10-25

    申请号：US12181

    申请日：1993-02-02

    申请人： Abbot F. Clark ,  Aaron L. Southren

    发明人： Abbot F. Clark ,  Aaron L. Southren

    IPC分类号： A61K31/57 ,  A61K31/56 ,  A61K31/33

    CPC分类号： A61K31/57 ,  Y10S514/914 ,  Y10S514/922

    摘要： Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.

    摘要翻译： 公开了可用于治疗眼部炎症的药物组合物和用这些组合物治疗眼部炎症的方法。 组合物含有糖皮质激素和四氢皮质醇的组合。 四氢皮质醇用于基本上防止眼睛压力的任何显着增加，否则患者可能会经历该组合物的糖皮质激素成分的副作用。 因此，两种组分的治疗相互作用允许使用糖皮质激素的有效的抗炎特性，而不用担心升高眼内压。 还公开了防止全身或局部皮质类固醇治疗引起的眼压升高的方法。 该方法涉及向接受这种治疗的患者施用含有四氢皮质醇的药物组合物。